openPR Logo
Press release

Graft Versus Host Disease GvHD Treatment Market: Outlook Continues to Remain Positive by 2016 – 2026

08-13-2018 12:50 PM CET | Health & Medicine

Press release from: Future Market Insights

Graft Versus Host Disease GvHD Treatment Market: Outlook

Graft versus Host disease occurs after a stem cell or bone marrow transplant. High dose treatment destroy cancer cells along with that it simultaneously destroys healthy cells. Stem cell and bone marrow transplant treatments are used in reconstructing damaged cells, surrounding cancer tumors. Normally after high dose treatment, patient receives bone marrow from a donor through drip which resumes production of blood cells. Graft versus Host Disease occurs when certain types of white blood cells. This is caused due to the transplanted cells (graft) see recipient’s body (host) as exotic, thus transplanted cells attack the host body.

It is tough to diagnose who might develop GvHD after a transplant. Mild form of GvHD is observed in few cases. While in certain cases GvHD may be fatal. GvHD do not occur when recipient receives their own cells through autologous transplant. Prior to a transplant, cells from possible donors are screened to realize how strictly they match the recipient. Chances of GvHD are reduced, or symptoms will be milder, when the match is close.

A sample of this report is available upon request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1401

There are two forms of GvHD:

Acute graft versus host disease (aGvHD).

Chronic graft versus host disease (cGvHD).

Graft Versus Host Disease (GvHD) Treatment Market: Drivers and Restraints

Presently, graft versus host disease (GvHD) market is driven by increase in number of incidence and prevalence of cancer patients which are treated by chemotherapy treatment. Graft versus host disease (GvHD) global market is also fueled by increase in number of bone marrow transplants been carried around the globe to treat specific types of cancers. Increase in allogeneic hematopoietic stem cell transplant will play key role in global market for graft versus host disease (GvHD). However, cost linked with recent clinical trials and authorizations would acts as a major restraint for graft versus host disease (GvHD) global market.

Graft versus Host Disease (GvHD) Treatment: Segmentation

Global Graft versus host disease (GvHD) marketis segmented into following product type, and region:

Based on product type segment, global Graft versus host disease (GvHD) market is segmented into:

Monoclonal antibodies

mTOR inhibitors

Tyrosine kinase inhibitors

Thalidomide

Etanercept

Graft versus Host Disease (GvHD) Treatment Market: Overview

The global market graft versus host disease (GvHD) treatmentis expected to register a healthy CAGR during the forecast period. Innovative development of novel technologies, and increase in the number of cancer patients seeking for chemotherapy treatment is expected to drive the growth of graft versus host disease (GvHD) treatmentmarket in the forecast period (2016-2026).

Graft versus Host Disease (GvHD) Treatment Market: Region-wise Outlook

Depending on geographic regions, global medical graft versus host disease (GvHD) treatment marketis segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Asia Pacific Excluding Japan, Japan and Middle East & Africa. In terms of region Europe holds for the largest market shares in global market graft versus host disease (GvHD) treatmentowing to improvements in medical research, clinical trials, growing geriatric population with cancer indication. Whereas, North America and Asia-Pacific is likely to grow at a substantial growth due to large incidence and prevalence of cancer patientswill contribute to the global graft versus host disease (GvHD) treatmentmarket value showing a healthy CAGR during the forecast period, 2016-2026.The market for graft versus host disease (GvHD) treatment in various regions is particularly driven by gradually increasing awareness, rising number of chemotherapies and adoption of advanced technologies in cancer treatment.

To view TOC of this report is available upon request @ https://www.futuremarketinsights.com/toc/rep-gb-1401

Graft versus Host Disease (GvHD) Treatment Market: Key Players

Some of the key participating global players in graft versus host disease (GvHD) treatment global market are Sanofi, Novartis AG, Neovii Biotech GmbH,Merck & Co., Astellas Pharma Inc.,Soligenix, Inc., Mesoblast Ltd and others.

About Us
Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centres in the U.S. and India.

FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customised and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

Contact Us
U.S. Office
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Web:https://www.futuremarketinsights.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Graft Versus Host Disease GvHD Treatment Market: Outlook Continues to Remain Positive by 2016 – 2026 here

News-ID: 1176463 • Views:

More Releases from Future Market Insights

Aerospace Fluid Conveyance System Market to Reach USD 4.3 Billion by 2035 with Innovative Components and Growth
Aerospace Fluid Conveyance System Market to Reach USD 4.3 Billion by 2035 with I …
The global Aerospace Fluid Conveyance System Market is witnessing steady growth, driven by the increasing demand for advanced fluid handling solutions across commercial and military aircraft. Valued at USD 3.1 billion in 2025, the market is projected to reach USD 4.3 billion by 2035, registering a healthy CAGR of 3.4%. Both established and emerging manufacturers are actively innovating to meet the evolving needs of the aviation sector. Market Dynamics and Growth
Automotive Starter and Alternator Market to Reach USD 45.4 Billion by 2035 Amid Electrification Trends
Automotive Starter and Alternator Market to Reach USD 45.4 Billion by 2035 Amid …
The global Automotive Starter and Alternator Market is on track for substantial expansion, driven by rapid advancements in vehicle technology and the growing focus on electrification. Valued at USD 29.3 billion in 2025, the market is projected to reach USD 45.4 billion by 2035, registering a CAGR of 4.5% during the forecast period. The growth reflects the automotive industry's continuous evolution toward fuel-efficient and sustainable systems that integrate reliability, performance,
Connected Aircraft Market Soars to USD 63.6 Billion by 2035, Driven by Connectivity and Digital Innovation
Connected Aircraft Market Soars to USD 63.6 Billion by 2035, Driven by Connectiv …
The global Connected Aircraft Market is poised for transformative growth, projected to rise from USD 6.8 billion in 2025 to USD 63.6 billion by 2035, registering an impressive CAGR of 25.1% over the forecast period. This surge is being fueled by airlines' growing focus on enhancing operational efficiency, passenger experience, and safety through advanced connectivity solutions. Industry leaders such as Honeywell International Inc., Thales Group, Raytheon Technologies Corporation, BAE Systems PLC,
Slingshot/3-Wheeled Motorcycle Market Set to Hit USD 1.8 Billion by 2035 Driven by Design and Innovation
Slingshot/3-Wheeled Motorcycle Market Set to Hit USD 1.8 Billion by 2035 Driven …
The global Slingshot/3-Wheeled Motorcycle Market is on track to witness sustained growth, driven by shifting consumer lifestyles, urban mobility trends, and a rising interest in alternative transportation. Valued at USD 1.3 billion in 2025, the market is projected to reach USD 1.8 billion by 2035, expanding at a CAGR of 2.9%. During the early growth phase (2021-2025), the market experiences gradual expansion, fueled by consumers' growing appetite for distinctive vehicles that

All 5 Releases


More Releases for GvHD

Graft Versus Host Disease (GVHD) - Drug Pipeline Landscape, 2022
Graft Versus Host disease (GVHD) is an immune mediated systemic disorder associated with complex interaction between donor and recipient adaptive immunity. It is a common complication after hematopoietic stem cell transplant (HCT), here the graft recognizes the host as a foreign and attack the recipient's body cell. GvHD is of two types: acute GvHD - which develops within 100 days of transplantation and chronic GvHD - which develops after 100
Graft Versus Host Disease (GvHD) Market Expected to Expand at a Steady 2022-2028 …
Coherent Market Insights have added a new research study on Title Graft Versus Host Disease (GvHD) Market, Global Outlook and Forecast 2022-2028 with detailed information & Key Players Such as Gvhd market are Sanofi, Novartis AG, Neovii Biotech GmbH, Merck & Co., Astellas Pharma Inc., Soligenix, Inc., and Mesoblast Ltd. The Study provides in-depth comprehensive analysis includes Clear Market definitions, classifications, manufacturing processes, cost structures, development policies and plans. The
Graft Versus Host Disease GvHD Treatment Market Investment Research Report 2016- …
Graft versus Host disease occurs after a stem cell or bone marrow transplant. High dose treatment destroy cancer cells along with that it simultaneously destroys healthy cells. Stem cell and bone marrow transplant treatments are used in reconstructing damaged cells, surrounding cancer tumors. Normally after high dose treatment, patient receives bone marrow from a donor through drip which resumes production of blood cells. Graft versus Host Disease occurs when certain
Graft Versus Host Disease GvHD Treatment Market Revenue and Value Chain 2016-202 …
Graft versus Host disease occurs after a stem cell or bone marrow transplant. High dose treatment destroy cancer cells along with that it simultaneously destroys healthy cells. Stem cell and bone marrow transplant treatments are used in reconstructing damaged cells, surrounding cancer tumors. Normally after high dose treatment, patient receives bone marrow from a donor through drip which resumes production of blood cells. Graft versus Host Disease occurs when certain
Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2017, provides an overview of the Graft Versus Host Disease (GVHD) (Immunology) pipeline landscape. Graft-versus-host disease (GVHD) is a complication that can occur after
Graft Versus Host Disease (GvHD) Market - Global Industry Analysis 2024
During any transplant of stem cell and bone marrow some complications arises that may be mild or severe, those are the graft versus host disease (Gvhd) they occur especially in immune-compromised patients. During cancer treatment, the radioactive agents or the chemicals affects the healthy cells along with the cancer cells. Reconstruction of body cells affected during cancer treatment can be fixed using stem cell and bone marrow transplant. Following a